User menu

Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Bibliographic reference Medves, Sandrine ; Demoulin, Jean-Baptiste. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.. In: Journal of Cellular and Molecular Medicine, Vol. 16, no.2, p. 237-48 (2012)
Permanent URL http://hdl.handle.net/2078.1/145441
  1. Ren Ruibao, Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia, 10.1038/nrc1567
  2. Toffalini F., Demoulin J.-B., New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases, 10.1182/blood-2010-04-279752
  3. Lacronique V., A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia, 10.1126/science.278.5341.1309
  4. Santoro M., Melillo R. M., Fusco A., RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture, 10.1530/eje.1.02289
  5. Kwak Eunice L., Bang Yung-Jue, Camidge D. Ross, Shaw Alice T., Solomon Benjamin, Maki Robert G., Ou Sai-Hong I., Dezube Bruce J., Jänne Pasi A., Costa Daniel B., Varella-Garcia Marileila, Kim Woo-Ho, Lynch Thomas J., Fidias Panos, Stubbs Hannah, Engelman Jeffrey A., Sequist Lecia V., Tan WeiWei, Gandhi Leena, Mino-Kenudson Mari, Wei Greg C., Shreeve S. Martin, Ratain Mark J., Settleman Jeffrey, Christensen James G., Haber Daniel A., Wilner Keith, Salgia Ravi, Shapiro Geoffrey I., Clark Jeffrey W., Iafrate A. John, Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer, 10.1056/nejmoa1006448
  6. Mitelman F Johansson B Mertens F Mitelman database of chromosome aberrations and gene fusions in cancer http://cgapncinihgov/Chromosomes/Mitelman 2011
  7. Novo Francisco J, de Mendíbil Iñigo, Vizmanos José L, 10.1186/1471-2164-8-33
  8. Lacronique, Blood., 95, 2076 (2000)
  9. Lierman E., Van Miegroet H., Beullens E., Cools J., Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen, 10.3324/haematol.2009.007328
  10. Weinstein I. B., Joe A., Felsher D., Oncogene Addiction, 10.1158/0008-5472.can-07-3293
  11. Gruber Franz, Mustjoki Satu, Porkka Kimmo, Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia, 10.1111/j.1365-2141.2009.07666.x
  12. Chan Wayne W., Wise Scott C., Kaufman Michael D., Ahn Yu Mi, Ensinger Carol L., Haack Torsten, Hood Molly M., Jones Jennifer, Lord John W., Lu Wei Ping, Miller David, Patt William C., Smith Bryan D., Petillo Peter A., Rutkoski Thomas J., Telikepalli Hanumaiah, Vogeti Lakshminarayana, Yao Tony, Chun Lawrence, Clark Robin, Evangelista Peter, Gavrilescu L. Cristina, Lazarides Katherine, Zaleskas Virginia M., Stewart Lance J., Van Etten Richard A., Flynn Daniel L., Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036, 10.1016/j.ccr.2011.03.003
  13. David M., Cross N. C. P., Burgstaller S., Chase A., Curtis C., Dang R., Gardembas M., Goldman J. M., Grand F., Hughes G., Huguet F., Lavender L., McArthur G. A., Mahon F. X., Massimini G., Melo J., Rousselot P., Russell-Jones R. J., Seymour J. F., Smith G., Stark A., Waghorn K., Nikolova Z., Apperley J. F., Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders, 10.1182/blood-2006-05-024828
  14. Pardanani Animesh, Tefferi Ayalew, Targeting myeloproliferative neoplasms with JAK inhibitors : , 10.1097/moh.0b013e3283439964
  15. Gerber David E., Minna John D., ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time, 10.1016/j.ccr.2010.11.033
  16. Chapman Paul B., Hauschild Axel, Robert Caroline, Haanen John B., Ascierto Paolo, Larkin James, Dummer Reinhard, Garbe Claus, Testori Alessandro, Maio Michele, Hogg David, Lorigan Paul, Lebbe Celeste, Jouary Thomas, Schadendorf Dirk, Ribas Antoni, O'Day Steven J., Sosman Jeffrey A., Kirkwood John M., Eggermont Alexander M.M., Dreno Brigitte, Nolop Keith, Li Jiang, Nelson Betty, Hou Jeannie, Lee Richard J., Flaherty Keith T., McArthur Grant A., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, 10.1056/nejmoa1103782
  17. Tsai J., Lee J. T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N. K., Sproesser K., Li L., Smalley K. S. M., Fong D., Zhu Y.-L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.-H., Schlessinger J., Zhang K. Y. J., West B. L., Powell B., Habets G., Zhang C., Ibrahim P. N., Hirth P., Artis D. R., Herlyn M., Bollag G., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, 10.1073/pnas.0711741105
  18. Cools Jan, DeAngelo Daniel J., Gotlib Jason, Stover Elizabeth H., Legare Robert D., Cortes Jorges, Kutok Jeffrey, Clark Jennifer, Galinsky Ilene, Griffin James D., Cross Nicholas C.P., Tefferi Ayalew, Malone James, Alam Rafeul, Schrier Stanley L., Schmid Janet, Rose Michal, Vandenberghe Peter, Verhoef Gregor, Boogaerts Marc, Wlodarska Iwona, Kantarjian Hagop, Marynen Peter, Coutre Steven E., Stone Richard, Gilliland D. Gary, A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome, 10.1056/nejmoa025217
  19. Gandhi M, Dillon L W, Pramanik S, Nikiforov Y E, Wang Y-H, DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells, 10.1038/onc.2009.502
  20. Burrow Allison A, Williams Laura E, Pierce Levi CT, Wang Yuh-Hwa, Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites, 10.1186/1471-2164-10-59
  21. NOVO F, VIZMANOS J, Chromosome translocations in cancer: computational evidence for the random generation of double-strand breaks, 10.1016/j.tig.2006.02.001
  22. Erben P., Gosenca D., Muller M. C., Reinhard J., Score J., del Valle F., Walz C., Mix J., Metzgeroth G., Ernst T., Haferlach C., Cross N. C. P., Hochhaus A., Reiter A., Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis, 10.3324/haematol.2009.016345
  23. Koschmieder S., Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis, 10.1182/blood-2003-12-4369
  24. Bueno María J., Pérez de Castro Ignacio, Gómez de Cedrón Marta, Santos Javier, Calin George A., Cigudosa Juan C., Croce Carlo M., Fernández-Piqueras José, Malumbres Marcos, Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression, 10.1016/j.ccr.2008.04.018
  25. Futami M, Hatano T, Soda Y, Kobayashi S, Miyagishi M, Tojo A, RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells, 10.1038/leu.2008.60
  26. Koldehoff M., Kordelas L., Beelen D. W., Elmaagacli A. H., Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib, 10.3324/haematol.2009.016063
  27. Zheng Xiaomin, Oancea Claudia, Henschler Reinhard, Moore Malcolm A. S., Ruthardt Martin, Reciprocal t(9;22) ABL/BCR Fusion Proteins: Leukemogenic Potential and Effects on B Cell Commitment, 10.1371/journal.pone.0007661
  28. Medves S, Duhoux F P, Ferrant A, Toffalini F, Ameye G, Libouton J-M, Poirel H A, Demoulin J-B, KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia, 10.1038/leu.2010.13
  29. Barjesteh van Waalwijk van Doorn-Khosrovani Sahar, Spensberger Dominik, de Knegt Yvonne, Tang Michelle, Löwenberg Bob, Delwel Ruud, Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia, 10.1038/sj.onc.1208588
  30. Griesinger Frank, Janke Angela, Podleschny Martina, Bohlander Stefan K., Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line, 10.1046/j.1365-2141.2002.03850.x
  31. Vu H A, Xinh P T, Masuda M, Motoji T, Toyoda A, Sakaki Y, Tokunaga K, Sato Y, FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation, 10.1038/sj.leu.2404266
  32. Golub T R, Goga A, Barker G F, Afar D E, McLaughlin J, Bohlander S K, Rowley J D, Witte O N, Gilliland D G, Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia., 10.1128/mcb.16.8.4107
  33. Tognon C. E., Mackereth C. D., Somasiri A. M., McIntosh L. P., Sorensen P. H. B., Mutations in the SAM Domain of the ETV6-NTRK3 Chimeric Tyrosine Kinase Block Polymerization and Transformation Activity, 10.1128/mcb.24.11.4636-4650.2004
  34. Jousset C., A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRbeta oncoprotein, 10.1093/emboj/16.1.69
  35. De Keersmaecker K., Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32), 10.1182/blood-2004-12-4897
  36. McWhirter J R, Galasso D L, Wang J Y, A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins., 10.1128/mcb.13.12.7587
  37. McWhirter John R, Wang Jean YJ, Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein, 10.1038/sj.onc.1201342
  38. Smith Kristen M., Yacobi Rinat, Van Etten Richard A., Autoinhibition of Bcr-Abl through Its SH3 Domain, 10.1016/s1097-2765(03)00274-0
  39. He Y., The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl, 10.1182/blood.v99.8.2957
  40. Mian A A, Oancea C, Zhao Z, Ottmann O G, Ruthardt M, Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL, 10.1038/leu.2009.194
  41. Ross Theodora S., Gilliland D. Gary, Transforming Properties of the Huntingtin Interacting Protein 1/ Platelet-derived Growth Factor β Receptor Fusion Protein, 10.1074/jbc.274.32.22328
  42. Medves S., Noel L. A., Montano-Almendras C. P., Albu R. I., Schoemans H., Constantinescu S. N., Demoulin J.-B., Multiple oligomerization domains of KANK1-PDGFR  are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK, 10.3324/haematol.2011.040147
  43. Baumann Heinz, Kunapuli Padmaja, Tracy Erin, Cowell John K., The Oncogenic Fusion Protein-tyrosine Kinase ZNF198/Fibroblast Growth Factor Receptor-1 Has Signaling Function Comparable with Interleukin-6 Cytokine Receptors, 10.1074/jbc.m300018200
  44. Zhao, Nat Struct Biol., 9, 117 (2002)
  45. De Keersmaecker Kim, Rocnik Jennifer L., Bernad Rafael, Lee Benjamin H., Leeman Dena, Gielen Olga, Verachtert Hanne, Folens Cedric, Munck Sebastian, Marynen Peter, Fornerod Maarten, Gilliland D. Gary, Cools Jan, Kinase Activation and Transformation by NUP214-ABL1 Is Dependent on the Context of the Nuclear Pore, 10.1016/j.molcel.2008.05.005
  46. Lelièvre Hélène, Chevrier Véronique, Tassin Anne-Marie, Birnbaum Daniel, Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome, 10.1186/1476-4598-7-30
  47. Mikolajka Aleksandra, Yan Xiumin, Popowicz Grzegorz M., Smialowski Pawel, Nigg Erich A., Holak Tad A., Structure of the N-terminal Domain of the FOP (FGFR1OP) Protein and Implications for its Dimerization and Centrosomal Localization, 10.1016/j.jmb.2006.03.070
  48. Rigby Sue, Huang Yuanxue, Streubel Berthold, Chott Andreas, Du Ming-Qing, Turner Suzanne D., Bacon Chris M., The Lymphoma-associated Fusion Tyrosine Kinase ITK-SYK Requires Pleckstrin Homology Domain-mediated Membrane Localization for Activation and Cellular Transformation, 10.1074/jbc.m109.034272
  49. Pechloff Konstanze, Holch Julian, Ferch Uta, Schweneker Marc, Brunner Kristina, Kremer Markus, Sparwasser Tim, Quintanilla-Martinez Leticia, Zimber-Strobl Ursula, Streubel Berthold, Gewies Andreas, Peschel Christian, Ruland Jürgen, The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma, 10.1084/jem.20092042
  50. Tort Frederic, Pinyol Magda, Pulford Karen, Roncador Giovanna, Hernandez Lluis, Nayach Iracema, Kluin-Nelemans Hanneke C, Kluin Philip, Touriol Christian, Delsol Georges, Mason David, Campo Elias, Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma, 10.1038/labinvest.3780249
  51. Touriol, Blood., 95, 3204 (2000)
  52. Constantinescu Stefan N, Huang Lily Jun-shen, Nam Hyung-song, Lodish Harvey F, The Erythropoietin Receptor Cytosolic Juxtamembrane Domain Contains an Essential, Precisely Oriented, Hydrophobic Motif, 10.1016/s1097-2765(01)00185-x
  53. Bell C. A., Tynan J. A., Hart K. C., Meyer A. N., Robertson S. C., Donoghue D. J., Rotational Coupling of the Transmembrane and Kinase Domains of the Neu Receptor Tyrosine Kinase, 10.1091/mbc.11.10.3589
  54. Toffalini Federica, Hellberg Carina, Demoulin Jean-Baptiste, Critical Role of the Platelet-derived Growth Factor Receptor (PDGFR) β Transmembrane Domain in the TEL-PDGFRβ Cytosolic Oncoprotein, 10.1074/jbc.m109.076638
  55. Griffith James, Black James, Faerman Carlos, Swenson Lora, Wynn Michael, Lu Fan, Lippke Judith, Saxena Kumkum, The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain, 10.1016/s1097-2765(03)00505-7
  56. Stover E. H., Chen J., Folens C., Lee B. H., Mentens N., Marynen P., Williams I. R., Gilliland D. G., Cools J., Activation of FIP1L1-PDGFR  requires disruption of the juxtamembrane domain of PDGFR  and is FIP1L1-independent, 10.1073/pnas.0601192103
  57. Lahortiga I., Akin C., Cools J., Wilson T. M., Mentens N., Arthur D. C., Maric I., Noel P., Kocabas C., Marynen P., Lessin L. S., Wlodarska I., Robyn J., Metcalfe D. D., Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion, 10.3324/haematol.11836
  58. Vu Hoang Anh, Xinh Phan Thi, Kano Yasuhiko, Tokunaga Katsushi, Sato Yuko, The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation, 10.1016/j.bbrc.2009.03.157
  59. Chiara Federica, Bishayee Subal, Heldin Carl-Henrik, Demoulin Jean-Baptiste, Autoinhibition of the Platelet-derived Growth Factor β-Receptor Tyrosine Kinase by Its C-terminal Tail, 10.1074/jbc.m314070200
  60. DEMOULIN Jean-Baptiste, SEO Jeong Kon, EKMAN Simon, GRAPENGIESSER Eva, HELLMAN Ulf, RÖNNSTRAND Lars, HELDIN Carl-Henrik, Ligand-induced recruitment of Na+/H+-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF, 10.1042/bj20030385
  61. Hantschel Oliver, Nagar Bhushan, Guettler Sebastian, Kretzschmar Jana, Dorey Karel, Kuriyan John, Superti-Furga Giulio, A Myristoyl/Phosphotyrosine Switch Regulates c-Abl, 10.1016/s0092-8674(03)00191-0
  62. Zhang Jianming, Adrián Francisco J., Jahnke Wolfgang, Cowan-Jacob Sandra W., Li Allen G., Iacob Roxana E., Sim Taebo, Powers John, Dierks Christine, Sun Fangxian, Guo Gui-Rong, Ding Qiang, Okram Barun, Choi Yongmun, Wojciechowski Amy, Deng Xianming, Liu Guoxun, Fendrich Gabriele, Strauss André, Vajpai Navratna, Grzesiek Stephan, Tuntland Tove, Liu Yi, Bursulaya Badry, Azam Mohammad, Manley Paul W., Engen John R., Daley George Q., Warmuth Markus, Gray Nathanael S., Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors, 10.1038/nature08675
  63. Duhoux Francois P., Auger Nathalie, De Wilde Sigrid, Wittnebel Sebastian, Ameye Geneviève, Bahloula Khadija, Van den Berg Catherine, Libouton Jeanne-Marie, Saussoy Pascale, Grand Francis H., Demoulin Jean-Baptiste, Poirel Hélène A., The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias, 10.1016/j.leukres.2011.02.011
  64. Roumiantsev S., The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase, 10.1182/blood.v97.1.4
  65. Zhang X., The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype, 10.1182/blood.v97.1.277
  66. Thai M, Ting P Y, McLaughlin J, Cheng D, Müschen M, Witte O N, Colicelli J, ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1, 10.1038/leu.2010.268
  67. Morikawa, Int J Oncol., 23, 617 (2003)
  68. Vainchenker William, Dusa Alexandra, Constantinescu Stefan N., JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies, 10.1016/j.semcdb.2008.07.002
  69. Van Roosbroeck K., Cox L., Tousseyn T., Lahortiga I., Gielen O., Cauwelier B., De Paepe P., Verhoef G., Marynen P., Vandenberghe P., De Wolf-Peeters C., Cools J., Wlodarska I., JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma, 10.1182/blood-2010-06-291310
  70. Hazlehurst, Cancer Control., 16, 100 (2009)
  71. Turner S D, Alexander D R, Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells, 10.1038/sj.leu.2404125
  72. Wong Stephane, Witte Owen N., The BCR-ABL Story: Bench to Bedside and Back, 10.1146/annurev.immunol.22.012703.104753
  73. Voss Jan, Posern Guido, Hannemann Jürgen R, Wiedemann Leanne M, Turhan Ali G, Poirel Hélène, Bernard Olivier A, Adermann Knut, Kardinal Christian, Feller Stephan M, The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways, 10.1038/sj.onc.1203467
  74. De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O, Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases, 10.1038/leu.2008.242
  75. Toffalini F., Kallin A., Vandenberghe P., Pierre P., Michaux L., Cools J., Demoulin J.-B., The fusion proteins TEL-PDGFR  and FIP1L1-PDGFR  escape ubiquitination and degradation, 10.3324/haematol.2008.001149
  76. Essaghir Ahmed, Toffalini Federica, Knoops Laurent, Kallin Anders, van Helden Jacques, Demoulin Jean-Baptiste, Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data, 10.1093/nar/gkq149
  77. Palmer Ruth H., Vernersson Emma, Grabbe Caroline, Hallberg Bengt, Anaplastic lymphoma kinase: signalling in development and disease, 10.1042/bj20090387
  78. Wilbanks Alyson M., Mahajan Sudipta, Frank David A., Druker Brian J., Gilliland D.Gary, Carroll Martin, TEL/PDGFβR fusion protein activates STAT1 and STAT5, 10.1016/s0301-472x(00)00138-7
  79. Cain J. A., Xiang Z., O'Neal J., Kreisel F., Colson A., Luo H., Hennighausen L., Tomasson M. H., Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage, 10.1182/blood-2006-07-036335
  80. Hoelbl Andrea, Schuster Christian, Kovacic Boris, Zhu Bingmei, Wickre Mark, Hoelzl Maria A., Fajmann Sabine, Grebien Florian, Warsch Wolfgang, Stengl Gabriele, Hennighausen Lothar, Poli Valeria, Beug Hartmut, Moriggl Richard, Sexl Veronika, Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia : Stat5 in leukaemia maintenance, 10.1002/emmm.201000062
  81. Buitenhuis M., Verhagen L. P., Cools J., Coffer P. J., Molecular Mechanisms Underlying FIP1L1-PDGFRA-Mediated Myeloproliferation, 10.1158/0008-5472.can-06-4183
  82. Heath Carol, Cross Nicholas C. P., Critical Role of STAT5 Activation in Transformation Mediated by ZNF198-FGFR1, 10.1074/jbc.m308743200
  83. Pendergast Ann Marie, Quilliam Lawrence A., Cripe Larry D., Bassing Craig H., Dai Zonghan, Li Nanxin, Batzer Andreas, Rabun Kelly M., Der Channing J., Schlessinger Joseph, Gishizky Mikhail L., BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein, 10.1016/s0092-8674(05)80094-7
  84. Puil, EMBO J., 13, 764 (1994)
  85. Zebedin E., Simma O., Schuster C., Putz E. M., Fajmann S., Warsch W., Eckelhart E., Stoiber D., Weisz E., Schmid J. A., Pickl W. F., Baumgartner C., Valent P., Piekorz R. P., Freissmuth M., Sexl V., Leukemic challenge unmasks a requirement for PI3K  in NK cell-mediated tumor surveillance, 10.1182/blood-2008-02-139105
  86. Sattler Martin, Mohi M.Golam, Pride Yuri B, Quinnan Laura R, Malouf Nicole A, Podar Klaus, Gesbert Franck, Iwasaki Hiromi, Li Shaoguang, Van Etten Richard A, Gu Haihua, Griffin James D, Neel Benjamin G, Critical role for Gab2 in transformation by BCR/ABL, 10.1016/s1535-6108(02)00074-0
  87. Nguyen T. K., Rahmani M., Harada H., Dent P., Grant S., MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825, 10.1182/blood-2006-09-045039
  88. Sjöblom Tobias, Boureux Anthony, Rönnstrand Lars, Heldin Carl-Henrik, Ghysdael Jacques, Östman Arne, Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein, 10.1038/sj.onc.1203190
  89. Goss V. L., A common phosphotyrosine signature for the Bcr-Abl kinase, 10.1182/blood-2005-08-3399
  90. Kunapuli Padmaja, Somerville Robert, Still Ivan H, Cowell John K, ZNF198 protein, involved in rearrangement in myeloproliferative disease, forms complexes with the DNA repair-associated HHR6A/6B and RAD18 proteins, 10.1038/sj.onc.1206408
  91. Kunapuli Padmaja, Kasyapa Chitta S., Chin Suet-Feung, Caldas Carlos, Cowell John K., ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML, 10.1016/j.yexcr.2006.06.037
  92. Hosoya Noriko, Qiao Ying, Hangaishi Akira, Wang Lili, Nannya Yasuhito, Sanada Masashi, Kurokawa Mineo, Chiba Shigeru, Hirai Hisamaru, Ogawa Seishi, Identification of a SRC-like tyrosine kinase gene,FRK, fused withETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation, 10.1002/gcc.20147
  93. Armstrong Florence, Duplantier Marie-Michèle, Trempat Pascal, Hieblot Corinne, Lamant Laurence, Espinos Estelle, Racaud-Sultan Claire, Allouche Michèle, Campo Elias, Delsol Georges, Touriol Christian, Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells, 10.1038/sj.onc.1207813
  94. Armstrong Florence, Lamant Laurence, Hieblot Corinne, Delsol Georges, Touriol Christian, TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins, 10.1016/j.ejca.2006.12.005
  95. Kasyapa Chitta S., Kunapuli Padmaja, Cowell John K., HSPA1A is an important regulator of the stability and function of ZNF198 and its oncogenic derivative, ZNF198–FGFR1, 10.1002/jcb.21362
  96. Barnes, Oncogene., 24, 6432 (2005)
  97. Mao J.-H., Sun X.-Y., Liu J.-X., Zhang Q.-Y., Liu P., Huang Q.-H., Li K. K., Chen Q., Chen Z., Chen S.-J., As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia, 10.1073/pnas.1016311108
  98. Mak H H L, Peschard P, Lin T, Naujokas M A, Zuo D, Park M, Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr–Met, involves exclusion from the endocytic degradative pathway, 10.1038/sj.onc.1210522
  99. Tsukahara F., Maru Y., Bag1 directly routes immature BCR-ABL for proteasomal degradation, 10.1182/blood-2009-10-249623
  100. Bonvini, Cancer Res., 62, 1559 (2002)
  101. Bonvini Paolo, Rosa Henry Dalla, Vignes Nadia, Rosolen Angelo, Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin : Role of the Co-Chaperone Carboxyl Heat Shock Protein 70-Interacting Protein, 10.1158/0008-5472.can-03-3531
  102. Porter James R, Fritz Christian C, Depew Kristopher M, Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy, 10.1016/j.cbpa.2010.03.019
  103. Trepel Jane, Mollapour Mehdi, Giaccone Giuseppe, Neckers Len, Targeting the dynamic HSP90 complex in cancer, 10.1038/nrc2887
  104. Nguyen T. K., Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate, 10.1158/1078-0432.ccr-05-2282
  105. Beck Raphael, Verrax Julien, Gonze Thomas, Zappone Marianne, Pedrosa Rozangela Curi, Taper Henryk, Feron Olivier, Calderon Pedro Buc, Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death, 10.1016/j.bcp.2008.10.019
  106. Frantsve J., Schwaller J., Sternberg D. W., Kutok J., Gilliland D. G., Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation, 10.1128/mcb.21.10.3547-3557.2001
  107. Kamizono Shintaro, Hanada Toshikatsu, Yasukawa Hideo, Minoguchi Shigeru, Kato Reiko, Minoguchi Mayu, Hattori Kimihiko, Hatakeyama Shigetsugu, Yada Masayoshi, Morita Sumiyo, Kitamura Toshio, Kato Hirohisa, Nakayama Kei-ichi, Yoshimura Akihiko, The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2, 10.1074/jbc.m010074200
  108. Cacalano Nicholas A., Sanden David, Johnston James A., 10.1038/35074525
  109. Sakamoto Hiroshi, Tsukaguchi Toshiyuki, Hiroshima Sayuri, Kodama Tatsushi, Kobayashi Takamitsu, Fukami Takaaki A., Oikawa Nobuhiro, Tsukuda Takuo, Ishii Nobuya, Aoki Yuko, CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant, 10.1016/j.ccr.2011.04.004
  110. Wasag B., Lierman E., Meeus P., Cools J., Vandenberghe P., The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11), 10.3324/haematol.2010.036558
  111. Chase A., Grand F. H., Cross N. C. P., Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome, 10.1182/blood-2007-02-074286
  112. George P., Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3, 10.1182/blood-2004-09-3413
  113. Radujkovic A, Schad M, Topaly J, Veldwijk M R, Laufs S, Schultheis B S, Jauch A, Melo J V, Fruehauf S, Zeller W J, Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG, 10.1038/sj.leu.2403764
  114. Tong WG Estrov Z Wang Y et al The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells Invest New Drugs 10.1007/s10637-010-9465-8
  115. Wu L X, Xu J H, Zhang K Z, Lin Q, Huang X W, Wen C X, Chen Y Z, Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin, 10.1038/leu.2008.89